# A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

> **NCT03954041** · PHASE2 · TERMINATED · sponsor: **Remedy Pharmaceuticals, Inc.** · enrollment: 92 (actual)

## Conditions studied

- Brain Contusion

## Interventions

- **DRUG:** BIIB093
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03954041
- **Lead sponsor:** Remedy Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-06
- **Primary completion:** 2023-06-27
- **Final completion:** 2023-06-27
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Early completed due to strategic considerations, not for efficacy or safety reasons.
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03954041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03954041, "A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03954041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*